Leerink Partnrs Has Positive Outlook of ZNTL FY2025 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Research analysts at Leerink Partnrs upped their FY2025 earnings per share estimates for Zentalis Pharmaceuticals in a research report issued to clients and investors on Monday, November 10th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($1.90) for the year, up from their previous forecast of ($2.08). The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ Q4 2025 earnings at ($0.49) EPS, FY2026 earnings at ($1.81) EPS and FY2027 earnings at ($1.70) EPS.

A number of other equities analysts have also weighed in on the company. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Tuesday. Wall Street Zen downgraded Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Morgan Stanley dropped their target price on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating for the company in a research report on Wednesday. Wells Fargo & Company reduced their price target on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, August 7th. Finally, Wedbush reissued a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $5.03.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ ZNTL opened at $1.34 on Thursday. Zentalis Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $4.44. The stock has a market cap of $96.66 million, a PE ratio of -0.65 and a beta of 1.87. The firm has a fifty day moving average price of $1.54 and a 200-day moving average price of $1.45.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Monday, November 10th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.12.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ZNTL. Catalyst Funds Management Pty Ltd purchased a new stake in Zentalis Pharmaceuticals during the 2nd quarter valued at $31,000. Cerity Partners LLC boosted its stake in Zentalis Pharmaceuticals by 58.7% during the first quarter. Cerity Partners LLC now owns 20,501 shares of the company’s stock worth $33,000 after buying an additional 7,579 shares during the period. Qube Research & Technologies Ltd bought a new position in Zentalis Pharmaceuticals during the second quarter valued at $37,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Zentalis Pharmaceuticals in the second quarter valued at $38,000. Finally, Corient Private Wealth LLC bought a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter worth about $41,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.